What are the key takeaways from this Beyond Biotech episode?

Key insights include: **PROTAC catalytic mechanism:** Unlike traditional small molecules requiring a one-to-one drug-to-protein ratio, PROTACs recruit the cell's natural degradation machinery, then detach and repeat the process. This catalytic recycling means lower drug quantities can eliminate larger protein volumes, making PROTACs particularly effective against resistance mechanisms where tumors amplify protein production.; **Capital allocation framework for platform companies:** Arvinas uses a three-way triangulation when deciding which programs to advance internally versus partner: what the company can fund, what large pharma partners want to invest in, and what biotech investors will finance. Programs misaligned with investor timelines become partnership candidates, preserving internal capital for high-priority assets.; **Blood-brain barrier penetration via medicinal chemistry:** ARV-102, Arvinas's oral LRRK2 degrader targeting Parkinson's disease and progressive supranuclear palsy, crosses the blood-brain barrier through optimized molecular design alone, without active transporters or delivery vehicles. Phase 1 data confirmed CNS penetration, with next-phase trials planned before year-end 2026.

What did Randy Teal discuss on Beyond Biotech?

Arvinas CEO Randy Teal joins Beyond Biotech to discuss the FDA approval of vepdegestrant, the first PROTAC protein degrader to complete Phase 3 trials, explaining how the technology eliminates disease-causing proteins entirely rather than blocking them, and outlining the company's pipeline across oncology and neurodegenerative diseases. Key topics include: **PROTAC catalytic mechanism:** Unlike traditional small molecules requiring a one-to-one drug-to-protein ratio, PROTACs recruit the cell's natural degradation machinery, then detach and repeat the process. This catalytic recycling means lower drug quantities can eliminate larger protein volumes, making PROTACs particularly effective against resistance mechanisms where tumors amplify protein production.; **Capital allocation framework for platform companies:** Arvinas uses a three-way triangulation when deciding which programs to advance internally versus partner: what the company can fund, what large pharma partners want to invest in, and what biotech investors will finance. Programs misaligned with investor timelines become partnership candidates, preserving internal capital for high-priority assets..

How long is this episode of Beyond Biotech?

This episode is 35 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

Beyond Biotech

The first PROTAC is here. What comes next in protein degradation?

July 3, 2026

35 min episode · 2 min read

Randy Teal

Episode

35 min

Read time

2 min

Topics

Productivity, Relationships, Investing

AI-Generated Summary

Published Jul 3, 2026

Key Takeaways

✓PROTAC catalytic mechanism: Unlike traditional small molecules requiring a one-to-one drug-to-protein ratio, PROTACs recruit the cell's natural degradation machinery, then detach and repeat the process. This catalytic recycling means lower drug quantities can eliminate larger protein volumes, making PROTACs particularly effective against resistance mechanisms where tumors amplify protein production.
✓Capital allocation framework for platform companies: Arvinas uses a three-way triangulation when deciding which programs to advance internally versus partner: what the company can fund, what large pharma partners want to invest in, and what biotech investors will finance. Programs misaligned with investor timelines become partnership candidates, preserving internal capital for high-priority assets.
✓Blood-brain barrier penetration via medicinal chemistry: ARV-102, Arvinas's oral LRRK2 degrader targeting Parkinson's disease and progressive supranuclear palsy, crosses the blood-brain barrier through optimized molecular design alone, without active transporters or delivery vehicles. Phase 1 data confirmed CNS penetration, with next-phase trials planned before year-end 2026.
✓Pipeline readout timeline for 2026–2027: Multiple Arvinas programs reach first Phase 1 data within 12–18 months: BCL6 degrader for non-Hodgkin's lymphoma reads out late 2026; SBMA/Kennedy's disease degrader reports first-half 2027; HPK1 immuno-oncology trial starts Q3 2026. These simultaneous readouts will directly drive partnering, financing, and internal investment decisions.
✓Partnering strategy timing: Arvinas maintained ongoing briefings with Novartis on its androgen receptor degrader program for several years before finalizing the 2024 partnership. This signals that biotech companies should begin cultivating large pharma relationships at early clinical stages, not at Phase 2 completion, as deal timelines routinely span multiple years of relationship-building.

What It Covers

Arvinas CEO Randy Teal joins Beyond Biotech to discuss the FDA approval of vepdegestrant, the first PROTAC protein degrader to complete Phase 3 trials, explaining how the technology eliminates disease-causing proteins entirely rather than blocking them, and outlining the company's pipeline across oncology and neurodegenerative diseases.

Key Questions Answered

•PROTAC catalytic mechanism: Unlike traditional small molecules requiring a one-to-one drug-to-protein ratio, PROTACs recruit the cell's natural degradation machinery, then detach and repeat the process. This catalytic recycling means lower drug quantities can eliminate larger protein volumes, making PROTACs particularly effective against resistance mechanisms where tumors amplify protein production.
•Capital allocation framework for platform companies: Arvinas uses a three-way triangulation when deciding which programs to advance internally versus partner: what the company can fund, what large pharma partners want to invest in, and what biotech investors will finance. Programs misaligned with investor timelines become partnership candidates, preserving internal capital for high-priority assets.
•Blood-brain barrier penetration via medicinal chemistry: ARV-102, Arvinas's oral LRRK2 degrader targeting Parkinson's disease and progressive supranuclear palsy, crosses the blood-brain barrier through optimized molecular design alone, without active transporters or delivery vehicles. Phase 1 data confirmed CNS penetration, with next-phase trials planned before year-end 2026.
•Pipeline readout timeline for 2026–2027: Multiple Arvinas programs reach first Phase 1 data within 12–18 months: BCL6 degrader for non-Hodgkin's lymphoma reads out late 2026; SBMA/Kennedy's disease degrader reports first-half 2027; HPK1 immuno-oncology trial starts Q3 2026. These simultaneous readouts will directly drive partnering, financing, and internal investment decisions.
•Partnering strategy timing: Arvinas maintained ongoing briefings with Novartis on its androgen receptor degrader program for several years before finalizing the 2024 partnership. This signals that biotech companies should begin cultivating large pharma relationships at early clinical stages, not at Phase 2 completion, as deal timelines routinely span multiple years of relationship-building.

Notable Moment

Teal describes Kennedy's disease patients as having zero options to slow disease progression across decades of decline, positioning Arvinas's SBMA PROTAC program — which entered the clinic in 2026 — as potentially the first therapy capable of modifying the disease course through targeted protein degradation.

Know someone who'd find this useful?